in pictures and a few words
What it is and why it matters
It’s a quick heart scan with a low radiation dose. It shows calcium in the heart’s blood vessels — that is, plaque that has already built up there.
- No contrast: no strain on the kidneys and no allergy to the dye
- The result is one number on a special scale, from zero up
- One scan helps you understand your heart risk for years ahead
It sees your vessels, not an average
Usual risk scores are based on age, blood pressure and cholesterol — as averaged across many people. The scan looks at your own vessels.
Zero is good news
Zero means there’s no calcium in the heart’s vessels. In people over 45, the risk of a heart attack in the next 10 years is then very low.
- You can calmly focus on prevention: food, movement, sleep
- Pills — not by default if risk is low and there’s no family high cholesterol
- Repeat the scan in 5–7 years, or sooner if you’re under 50
Important. Zero with high “bad” or inherited cholesterol — don’t give up prevention.
What the numbers mean
The higher the number, the more plaque has already built up and the more active the plan.
- From 1 to 99 — plaque has only just started: step up prevention
- From 100 to 399 — most people need cholesterol pills
- From 300 — more active treatment; 400 and above — high risk, follow-up with a cardiologist
Who benefits most from the scan
The scan helps most those for whom the decision about cholesterol pills is a “50/50” call. Usually these are people aged 40 to 75.
- An early heart attack in your father before 55 or your mother before 65
- Women in menopause with borderline cholesterol
- Prediabetes and other metabolic disorders
Scan plus blood tests
The scan shows what has already built up. Blood tests show what is happening now. Together they give the full picture.
- A test for the number of “bad” cholesterol particles in the blood
- An inherited cholesterol particle — tested once
- A test for inflammation in the vessels
Calcium won’t dissolve, growth can stop
Calcium that has been found won’t disappear. But plaque growth can be stopped and plaque made calmer.
- The goal isn’t to bring the number to zero, but to keep it from growing fast
- Cholesterol pills and a healthy lifestyle usually help
- From a score of 100, “bad” cholesterol below 1.8 mmol/L (70 mg/dL)
If pills aren’t enough
If cholesterol doesn’t reach the target on pills, your doctor may add injections. You give them to yourself once every 2 weeks or once a month.
- Injections together with pills lower “bad” cholesterol more than pills alone
- Most often there’s a mild reaction at the injection site or a runny nose
Who should see a doctor first
The scan suits most adults, but sometimes a talk with your doctor comes first.
- Pregnancy — the scan must not be done because of radiation
- Women of childbearing age — discuss it with a doctor first
- Pressing chest pain on exertion — get checked, even if the result is zero
Important. Pills, injections and supplements from the plan are started and changed only together with your doctor.
In one sentence
The scan shows what has already built up in the heart’s vessels, blood tests show what is happening now; together they help you choose your own plan and stop plaque in time.
Key points
CAC score is a low-dose non-contrast cardiac CT that directly shows plaque already accumulated in the coronary arteries; the table shows where this snapshot helps and what studies have shown.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Heart attack risk in an adult without symptoms | directly sees plaque in your own arteries rather than an averaged population probability; reclassifies patients more accurately than an ASCVD score based on lipids alone | coronary calcium predicted coronary events in four racial and ethnic groups (Detrano, NEJM 2008); adding CAC refined coronary heart disease risk classification (Polonsky, JAMA 2010) |
| Score 0 — "power of zero" | the strongest negative predictor: a justified opportunity to work through prevention, no default statin if overall risk is low and there is no familial hypercholesterolemia | in people older than 45 years, 10-year myocardial infarction risk below 1% |
| A "50/50" statin decision (age 40–75 years, ASCVD risk 5–20% over 10 years), early myocardial infarction in the family, menopause, metabolic syndrome, Lp(a) > 50 mg/dL | with moderate lipid risk, CAC = 0 gives a justified reason to defer a statin, CAC > 100 a reason to start; with early myocardial infarction in the family and Lp(a) > 50 mg/dL, it shows how much of the risk has already been realized; the main indication follows the 2019 ACC/AHA guidelines | — |
| CAC 100–399 and ≥400 | grounds for a statin with an LDL target <1.8 mmol/L (70 mg/dL); at ≥300 — statin + ezetimibe ± a PCSK9 inhibitor, at ≥400 — also functional testing | in MESA, CAC > 300 carried a 9.67-fold higher risk of a coronary event than CAC 0 over a median of 3.8 years (Detrano, NEJM 2008) |
| High CAC and LDL above target on a statin plus ezetimibe | PCSK9 inhibitors lower LDL by 50–60% beyond the maximum statin dose and Lp(a) by 25–30% | FOURIER, 27,564 patients with established cardiovascular disease: evolocumab on top of a statin reduced the composite endpoint by 15% over 2.2 years, LDL fell from 2.4 to 0.8 mmol/L (from 92 to 30 mg/dL) (PMID 28304224); ODYSSEY OUTCOMES, 18,924 patients after acute coronary syndrome: alirocumab reduced the risk of major cardiovascular events by 15% |
How it helps
A test that sees plaque instead of calculating risk
When people talk about "assessing myocardial infarction risk," they usually mean risk scores — ASCVD, SCORE2, Framingham. These scores combine age, sex, blood pressure, LDL, diabetes, and smoking, then output the probability of an event over 10 years. This is a useful tool, but it has a fundamental limitation: it does not see your own blood vessel. It averages the population.
CAC score (coronary artery calcium) is a low-dose non-contrast computed tomography scan of the chest that measures coronary artery calcification using the Agatston scale. It is direct visualization of atherosclerotic plaque, not a probability.
After 10–20 years of elevated ApoB or hypertension, plaque calcifies. CT can see it. The ASCVD score cannot. That is why CAC can reclassify a patient — avoid a statin in someone who was "borderline" by risk score, or start aggressive therapy where the lipid panel looked reassuring.
What the Agatston score measures
The Agatston score sums the volume and density of calcified lesions across all coronary arteries. Calcification is a marker of mature atherosclerotic plaque.
The method has important characteristics:
- Low radiation dose — 0.5–1.5 mSv, roughly 2–8 months of natural background radiation (about 2.4 mSv per year on average).
- No contrast — no kidney burden, no allergic reactions.
- High reproducibility — interobserver variability <10%.
- 10–15-year prognosis — not a one-time snapshot, but a long-term predictor.
- Cost 100–250 USD in most countries — more accessible than angiography.
Agatston score categories
The score is divided into four clinically meaningful categories, each with its own strategy.
- Score 0 — Power of zero. No calcified plaque. This is the strongest negative predictor in people older than 45 years: 10-year myocardial infarction risk below 1%. Repeat in 5–7 years, especially with a family history.
- Score 1–99 — mild calcification. Atherosclerosis has started but is not yet mature. Intensify prevention — lifestyle, omega-3, ApoB and blood pressure control. A statin is not prescribed by default; the decision is individualized.
- Score 100–399 — moderate calcification. Equivalent to intermediate-high risk. Statin therapy is indicated for most patients, with aggressive LDL control to <1.8 mmol/L (70 mg/dL) and discussion of aspirin if there are no contraindications.
- Score ≥400 — high risk. Aggressive lipid-lowering (statin + ezetimibe ± PCSK9; discussed from CAC ≥300), blood pressure control, and discussion of functional testing (stress test, CT angiography). In MESA, CAC > 300 carried a 9.67-fold higher risk of a coronary event than CAC 0 over a median of 3.8 years (Detrano R, NEJM 2008, PMID 18367736).
In MESA, each doubling of CAC raised the risk of a major coronary event (myocardial infarction or coronary death) by 15–35% and of any coronary event by 18–39% (Detrano R, NEJM 2008, PMID 18367736).
| Score | Category | Action |
|---|---|---|
| 0 | no plaque | risk <1%, no default statin |
| 1–99 | mild | intensify prevention |
| 100–399 | moderate | statin, LDL <1.8 mmol/L (70 mg/dL); from 300 — statin+ezetimibe±PCSK9 |
| ≥400 | high | statin+ezetimibe±PCSK9 |
Who should have the test
CAC provides the most information not for everyone, but for a clearly defined subgroup — people in whom the statin decision is "50/50."
- Age 40–75 years + intermediate ASCVD risk (5–20% over 10 years) — to refine the statin decision. This is the main indication supported by the 2019 ACC/AHA guidelines.
- Family history of early myocardial infarction (father < 55 years, mother < 65 years) — regardless of lipid levels.
- Perimenopausal and postmenopausal women with borderline lipids — in women, the ASCVD score often underestimates risk.
- Patients who do not want to take a statin despite moderate lipid risk — CAC = 0 provides a justified reason to defer; CAC > 100 provides a reason to "start after all."
- Patients with metabolic syndrome, prediabetes, PCOS — for vascular age stratification.
- Lp(a) > 50 mg/dL — CAC helps show how much of the genetic risk has already been realized.
CAC together with other tests
CAC sees mature calcified plaque. Alongside it, physicians assess what calcium does not show:
- Lp(a) — a genetic risk factor that increases LDL atherogenicity and promotes aortic valve calcification. It is measured once as a blood test. More detail in the article Lp(a) — genetic cardiovascular risk factor.
- ApoB — the number of atherogenic particles in plasma. LDL shows cholesterol within these particles; ApoB shows their number. ApoB predicts risk more accurately, especially in metabolic syndrome.
- hsCRP — a marker of vascular inflammation and plaque instability. Plaque can be small but "hot."
- Endothelial dysfunction — an early stage of vascular injury that precedes plaque by 10–20 years. See Endothelium: foundation of vascular health.
Holistic protocol for different CAC levels
1. CAC = 0
- Confirm that there are no other high-risk markers: Lp(a), family history, ApoB > 100 mg/dL, hsCRP > 2 mg/L.
- Support: Mediterranean / DASH diet, movement 150+ min/week, omega-3 index >8%, vitamin D 50–80 ng/mL, sleep control.
- Do not prescribe a statin by default if overall risk is low and there is no familial hypercholesterolemia.
- Repeat in 5–7 years (earlier if younger than 50 years).
2. CAC 1–99
- Intensify prevention: ApoB target <80 mg/dL, blood pressure <120/80, omega-3 index >8%, insulin sensitivity index (HOMA-IR <1.5).
- Nutraceuticals: omega-3 EPA+DHA 2 g/day, magnesium (glycinate) 400 mg, vitamin D3 + K2 (MK-7) 100–200 μg, CoQ10 100–200 mg, pomegranate extract 250–500 mg for the endothelium.
- Lifestyle: smoking cessation (absolute priority), 7–8 h of sleep, strength + aerobic training.
- Statin decision: individualized, based on the totality of factors. In some patients, it is reasonable to start a low-dose statin (rosuvastatin 5–10 mg).
- A statin is not decided by CAC alone: the decision includes an assessment of overall risk; in a patient with CAC 50 and ApoB 60 mg/dL plus an excellent lifestyle, the statin decision is individualized.
3. CAC 100–399
- Statin therapy for most: rosuvastatin 10–20 mg or atorvastatin 20–40 mg with a target ApoB <70 mg/dL / LDL <1.8 mmol/L (70 mg/dL). At CAC ≥300 — statin + ezetimibe ± a PCSK9 inhibitor, as in section 4.
- Blood pressure control to <130/80, ideally 120/80 when possible.
- HbA1c <5.7%, fasting insulin <8 μIU/mL.
- Aspirin 75–100 mg — discussed individually if bleeding risk is not increased.
- Full carotid artery evaluation (internal carotid artery ultrasound), functional stress test if symptomatic.
- Holistic support: omega-3 2–4 g/day, CoQ10 200 mg (especially on a statin), polyphenols (pomegranate, cocoa, EGCG), magnesium 400 mg.
4. CAC ≥ 400
- Aggressive lipid-lowering (from CAC ≥300): statin + ezetimibe; if ApoB does not reach the target <65 mg/dL — add a PCSK9 inhibitor (alirocumab, evolocumab).
- Stress test and/or CT angiography to identify a functionally significant stenotic zone.
- Cardiologist: lifelong follow-up, discussion of revascularization if ischemia is present.
- Control of all modifiable factors: smoking — complete cessation, blood pressure, glycemia, weight, sleep, stress.
- Holistic support: the same nutraceuticals as for CAC 100–399, plus emphasis on the endothelial protocol (L-arginine 3–6 g, citrulline 3 g, BH4 regeneration with polyphenols).
PCSK9 inhibitor dosing in patients with high CAC
The protocol for CAC ≥300 mentions PCSK9 inhibitors; their doses and evidence are below. Evolocumab and alirocumab are monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Blocking PCSK9 increases the density of LDL receptors on hepatocytes and lowers LDL cholesterol by 50–60% beyond what the maximum statin dose achieves.
When to repeat
Changes accumulate slowly, so CAC does not need to be repeated every year: an informative interval is 3–5 years (1 year when selecting aggressive therapy).
- CAC > 400 in the recent past — repeating it every year is pointless unless the treatment plan is changing; the focus then is functional diagnostics and ApoB control.
Who does not need the test
- Age < 40 years without family history — calcification has not yet had time to develop, so the result may be falsely reassuring. ApoB and Lp(a) work better in younger people.
- Already established coronary artery disease, prior myocardial infarction, previous stenting/CABG — a statin is indicated regardless of the score, and the decision has already been made.
- End-stage systemic disease of any kind — the priority is different.
Who should see a doctor first
- Pregnancy — radiation exposure, an absolute contraindication.
- Women of reproductive age — discuss the test with a physician first.
- Do not ignore symptoms when CAC = 0 — typical angina requires evaluation regardless of the score. Score 0 does not exclude rupture of a young soft plaque.
- CAC = 0 with high ApoB or Lp(a) — do not stop prevention: this is still high risk.
When to seek care
- Age 40–75 years with intermediate ASCVD risk (5–20% over 10 years)
- Family history of coronary artery disease / myocardial infarction / stroke before age 60 years (men <55, women <65)
- Borderline lipids + uncertainty about a statin
- Metabolic syndrome, prediabetes, type 2 diabetes
- Lp(a) > 50 mg/dL (>125 nmol/L)
- hsCRP > 2 mg/L on repeated testing
- Desire for an objective assessment of vascular age
Bottom line
CAC score is the most accurate single screening test for cardiology risk in an asymptomatic adult. It does not replace the lipid panel and is not the same as "having the full workup," but it reclassifies patients more accurately than any risk score. Score 0 provides a justified opportunity to work through prevention; Score ≥300 justifies aggressive therapy.
The combination of CAC + ApoB + Lp(a) + hsCRP + omega-3 index gives the physician four different cross-sections of the same process: accumulated damage, current pressure, genetic background, and inflammation. This quartet is the basis of modern cardiovascular prevention, and it is exactly what the md_pereligyn protocol places above the ASCVD score.
I perform full vascular stratification (CAC, Lp(a), ApoB, omega-3 index, hsCRP, HOMA-IR) and create a personalized plan — which tests, in what order, and which holistic protocol fits your risk level; you can book a consultation.
Treat the vessel, not its complications.
Sources
- Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–1345. PMID 18367736
- Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010;303:1610–1616. PMID 20424251
Related articles: Endothelium: foundation of vascular health, Cholesterol without statins.
Key facts
- CAC score is a low-dose non-contrast CT (0.5–1.5 mSv) that directly visualizes plaque on the Agatston scale.
- Score 0 in adults over 45 means a 10-year MI risk below 1%; with CAC > 300 the risk of a coronary event is 9.67 times higher than with zero (MESA).
- CAC reclassifies a patient more accurately than an ASCVD score based on lipids alone: Score 0 provides a justified opportunity to work through prevention, Score ≥300 justifies aggressive therapy.
- CAC works together with ApoB, Lp(a), and hsCRP: it shows damage already accumulated, while they show current pressure, genetic background, and inflammation.
- CAC growth can be stopped: the goal is to keep the score from growing faster than 10–15% per year, and with a statin plus the holistic protocol this is achievable.




